KR100999247B1 - 콜라겐 생구조물 및 그 제조방법 및 용도 - Google Patents
콜라겐 생구조물 및 그 제조방법 및 용도 Download PDFInfo
- Publication number
- KR100999247B1 KR100999247B1 KR1020047015383A KR20047015383A KR100999247B1 KR 100999247 B1 KR100999247 B1 KR 100999247B1 KR 1020047015383 A KR1020047015383 A KR 1020047015383A KR 20047015383 A KR20047015383 A KR 20047015383A KR 100999247 B1 KR100999247 B1 KR 100999247B1
- Authority
- KR
- South Korea
- Prior art keywords
- collagen
- amnion
- biostructure
- biostructures
- present
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 330
- 108010035532 Collagen Proteins 0.000 title claims abstract description 330
- 229920001436 collagen Polymers 0.000 title claims abstract description 330
- 238000000034 method Methods 0.000 title claims abstract description 168
- 238000002360 preparation method Methods 0.000 title claims description 14
- 210000001691 amnion Anatomy 0.000 claims abstract description 322
- 210000004379 membrane Anatomy 0.000 claims abstract description 76
- 239000012528 membrane Substances 0.000 claims abstract description 76
- 210000002826 placenta Anatomy 0.000 claims abstract description 61
- 210000001136 chorion Anatomy 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 37
- 210000005152 placental membrane Anatomy 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 92
- 239000000203 mixture Substances 0.000 claims description 68
- 210000001519 tissue Anatomy 0.000 claims description 61
- 208000027418 Wounds and injury Diseases 0.000 claims description 55
- 206010052428 Wound Diseases 0.000 claims description 54
- 239000000463 material Substances 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 50
- 239000007943 implant Substances 0.000 claims description 47
- 238000001035 drying Methods 0.000 claims description 46
- 238000001356 surgical procedure Methods 0.000 claims description 43
- 239000000017 hydrogel Substances 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 230000001413 cellular effect Effects 0.000 claims description 25
- 239000003242 anti bacterial agent Substances 0.000 claims description 24
- 229940088710 antibiotic agent Drugs 0.000 claims description 22
- 230000007547 defect Effects 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 239000003599 detergent Substances 0.000 claims description 21
- 238000003860 storage Methods 0.000 claims description 20
- 102000016359 Fibronectins Human genes 0.000 claims description 16
- 108010067306 Fibronectins Proteins 0.000 claims description 16
- 230000001605 fetal effect Effects 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- -1 anti-inflammatory Substances 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 13
- 230000036571 hydration Effects 0.000 claims description 12
- 238000006703 hydration reaction Methods 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 229920002674 hyaluronan Polymers 0.000 claims description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000000399 orthopedic effect Effects 0.000 claims description 9
- 239000008174 sterile solution Substances 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 8
- 230000003239 periodontal effect Effects 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 206010046543 Urinary incontinence Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 6
- 239000003429 antifungal agent Substances 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229960005475 antiinfective agent Drugs 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 150000002484 inorganic compounds Chemical class 0.000 claims description 5
- 229910010272 inorganic material Inorganic materials 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 208000032544 Cicatrix Diseases 0.000 claims description 4
- 206010072170 Skin wound Diseases 0.000 claims description 4
- 239000005667 attractant Substances 0.000 claims description 4
- 238000013130 cardiovascular surgery Methods 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 4
- 230000037387 scars Effects 0.000 claims description 4
- 230000037394 skin elasticity Effects 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- 206010010996 Corneal degeneration Diseases 0.000 claims description 3
- 208000001154 Dermoid Cyst Diseases 0.000 claims description 3
- 206010072138 Limbal stem cell deficiency Diseases 0.000 claims description 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 206010053615 Thermal burn Diseases 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 201000004781 bullous keratopathy Diseases 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000036575 thermal burns Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims description 2
- 206010006797 Burns first degree Diseases 0.000 claims description 2
- 206010006802 Burns second degree Diseases 0.000 claims description 2
- 206010006803 Burns third degree Diseases 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010029113 Neovascularisation Diseases 0.000 claims description 2
- 241001111421 Pannus Species 0.000 claims description 2
- 201000002154 Pterygium Diseases 0.000 claims description 2
- 206010039580 Scar Diseases 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000001088 anti-asthma Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 208000002352 blister Diseases 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 210000003516 pericardium Anatomy 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- FKJIJBSJQSMPTI-FHVQCLKSSA-N sodium;(4r)-4-[(10s,13r,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound [Na+].C1CC(=O)CC2CC(=O)C3C4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)CC3[C@]21C FKJIJBSJQSMPTI-FHVQCLKSSA-N 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 208000024222 Congenital skin disease Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 102000015731 Peptide Hormones Human genes 0.000 claims 1
- 108010038988 Peptide Hormones Proteins 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 208000031650 Surgical Wound Infection Diseases 0.000 claims 1
- 206010042736 Symblepharon Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 210000000713 mesentery Anatomy 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 abstract description 9
- 238000011069 regeneration method Methods 0.000 abstract description 9
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 238000002054 transplantation Methods 0.000 abstract description 8
- 210000002435 tendon Anatomy 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 210000003041 ligament Anatomy 0.000 abstract description 4
- 239000010410 layer Substances 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 36
- 238000012545 processing Methods 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 18
- 210000001508 eye Anatomy 0.000 description 16
- 229920003023 plastic Polymers 0.000 description 15
- 239000004033 plastic Substances 0.000 description 15
- 229910001220 stainless steel Inorganic materials 0.000 description 15
- 239000010935 stainless steel Substances 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000008223 sterile water Substances 0.000 description 14
- 210000003954 umbilical cord Anatomy 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229910052709 silver Inorganic materials 0.000 description 12
- 229940009188 silver Drugs 0.000 description 12
- 239000004332 silver Substances 0.000 description 12
- 239000004365 Protease Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 10
- 230000001070 adhesive effect Effects 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- 230000003169 placental effect Effects 0.000 description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000002985 plastic film Substances 0.000 description 8
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000003357 wound healing promoting agent Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 229920006255 plastic film Polymers 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 101800003838 Epidermal growth factor Proteins 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940116977 epidermal growth factor Drugs 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 5
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 229940126864 fibroblast growth factor Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229960002518 gentamicin Drugs 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 229960004023 minocycline Drugs 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003786 sclera Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- KDLRVYVGXIQJDK-FJTAYHGISA-N (2s,4r)-n-[2-chloro-1-[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)NC(C(C)Cl)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-FJTAYHGISA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 108010046075 Thymosin Proteins 0.000 description 4
- 102000007501 Thymosin Human genes 0.000 description 4
- 206010048038 Wound infection Diseases 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000316 bone substitute Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003966 growth inhibitor Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000006240 membrane receptors Human genes 0.000 description 4
- 108020004084 membrane receptors Proteins 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229910001961 silver nitrate Inorganic materials 0.000 description 4
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000007631 vascular surgery Methods 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 210000004128 D cell Anatomy 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 230000003851 biochemical process Effects 0.000 description 3
- 230000010478 bone regeneration Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000010030 laminating Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229940124583 pain medication Drugs 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 210000005059 placental tissue Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 208000007216 Furcation Defects Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241001621636 Pterygia Species 0.000 description 2
- 208000006981 Skin Abnormalities Diseases 0.000 description 2
- 239000004826 Synthetic adhesive Substances 0.000 description 2
- 208000010641 Tooth disease Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 239000004775 Tyvek Substances 0.000 description 2
- 229920000690 Tyvek Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000009432 framing Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000016446 peptide cross-linking Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 150000003378 silver Chemical class 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003356 suture material Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 238000009600 syphilis test Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000028016 temperature homeostasis Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000792264 Ceracia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 208000018035 Dental disease Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229910000737 Duralumin Inorganic materials 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000934359 Marmara Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 201000004195 band keratopathy Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- FXPVUWKFNGVHIZ-UHFFFAOYSA-L disodium;dodecyl sulfate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O FXPVUWKFNGVHIZ-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
- Y10T442/20—Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
- Y10T442/2525—Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
Abstract
Description
특징 | 본 발명의 콜라겐 생구조물 | 종래의 양막 |
혈청학적 측정 | 완전함: 항체선별(ATY); 알라닌 아미노 전이효소 선별(ALT); 간염 핵심항체(핵산 및 ELISA); B형간염 표면항원(핵산 및 ELISA); C형간염 바이러스항체(핵산 및 ELISA); HIV-1 및 HIV-2; HTLV-1 및 HTLV-2; 매독 테스트(RPR); CMV항체 테스트; C형간염 및 HIV 테스트(핵산테스트) | 불완전함: CMV 테스트 없음. |
저장 | 건조: 저열 진공으로 탈수; 냉동이나 냉장 필요 없음; 선반 보관 | 냉동: 배양 배지에 보관; 드라이 아이스 선적 및 냉동기/냉장기 필요 |
수술적 제조 | 수 분: 수분내 제조; 외과적 자리에서 직접 수화; 예를 들면 식염수 방울로 눈에서; 해동, 적시기 또는 린스 필요 없음. | 길다: 장황한 제조/해동/적심시간이 요구됨; 반드시 필터 뒷받침(backing)을 제거해야 함 |
수술적 취급 | 간단: 건조 중 흔들어 줄 수 있고; 외과적 자리에 도포되고 난 다음 그 자리에서 수화됨. | 장황함: 필터 페이퍼로부터 반드시 제거되어야 함; 외과수술 동안 둥글게 말리는 경향 있음(ball up); 외과적으로 가공하기 어려움 |
세포충실성 | 탈세포화: 최소한으로 경피세포가 없음; 최소한으로 세포 찌꺼기가 없음; 더 빨라진 재형성 | 사세포(dead cell)와 함께: 사세포가 존재; 임상적 증거가 긴 치료시간/높은 거부율을 나타낸다(일화적 증거) |
기질 | 없음: 기질이 없음(예를 들면 필터 뒷받침) | 있음: 니트로셀룰로오스/필터 페이퍼에 지지됨. |
살균(선택적) | 있음: 전자선 조사; 적어도 18kGy; 조직 안전성의 증가된 보증 | 없음: 항생제 및 글리세롤(유독성)을 포함하는 배지에 저장; 공식적인 최종적인 살균 없음 |
조직 투명도 | 반투명: 광학적으로 맑음 | 불투명: 우유빛 또는 탁한 외관 |
Claims (81)
- (a) 융모막으로부터 양막을 분리하는 단계;(b) 상기 양막이 효소와 접촉하지 않기 위하여 양막을 탈세포화하는 단계; 및(c) 상기 탈세포화된 양막을 탈수하는 단계를포함하는 양막과 융모막을 갖는 태반으로부터 콜라겐 생구조물을 제조하는 방법.
- 제1항에 있어서, 상기 방법은 상기 탈세포화된 양막을 세척하고 건조하는 것을 더욱 포함하는 방법.
- 제1항에 있어서, 상기 태반은 인간 태반인 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 태반은 제왕 절개 분만 또는 자연 분만을 겪은 인간 여성으로부터 온 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 방법은 상기 태반 막이 적어도 하나의 전염병에 대한 테스트를 한 공여자로부터 온 것인지를 결정하는 단계를 부가적으로 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 태반은 인간 여성의 태반인 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 태반은 출생 후 48시간 내에 공급된 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 방법은 (a)단계 후, (b)단계 전에 72시간까지 상기 양막을 저장하는 단계를 부가적으로 포함하는 것을 특징으로 하는 방법.
- 제8항에 있어서, 상기 저장은 (a)단계에서 얻은 상기 양막을 5일까지 냉장하는 것을 포함하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 상기 양막의 탈세포화는 상기 양막으로부터 모든 가시적인 세포 물질 및 세포찌거기를 제거하는 것을 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 상기 양막의 탈세포화는 상기 양막의 태아 측과 상기 양막의 산모 쪽 면과 태아 쪽 면에서 모든 가시적인 세포 물질 및 세포찌거기를 제거하는 것을 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 상기 양막의 탈세포화는 상기 막을 물리적으로 벗겨내는 것을 포함하는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 상기 양막의 탈세포화는 용액을 갖는 세제로 상기 양막을 탈세포화는 것을 포함하는 것을 특징으로 하는 방법.
- 제13항에 있어서, 상기 용액을 갖는 세제는 0.01-1.0% 데옥시콜린산(deoxycholic acid) 나트륨 염 1수화물을 포함하는 용액인 것을 특징으로 하는 방법.
- 제13항에 있어서, 상기 용액을 갖는 세제는 비이온성 세제, 트리톤 X-100, 음이온성 세제 및 황산도데실나트륨(SDS) 또는 그것의 혼합물로 구성된 군으로 부터 선택된 것을 특징으로 하는 방법.
- 제12항에 있어서, 상기 물리적 벗겨냄은 세포 스크레이퍼(scraper)를 가지고 벗겨내는 것을 포함하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 상기 양막의 탈세포화는 살균 용액에서 수행되는 것을 특징으로 하는 방법.
- 제2항에 있어서, 상기 양막의 세척은 살균 용액에서 수행되는 것을 특징으로 하는 방법.
- 제2항에 있어서, 상기 탈세포화된 양막의 건조는 35℃에서 50℃에서 수행되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 상기 방법은 (d) 양막 래미네이트(laminate)를 형성하기 위하여 적어도 두 개의 상기 탈세포화 및 탈수화 양막을 서로 접촉시켜 적층하는 단계를 추가로 포함하는 것을 특징으로 하는 방법.
- 삭제
- 삭제
- 제20항에 있어서, 상기 방법은 적어도 두 개의 상기 양막 래미네이트를 복잡한 3차원 스캐폴드(complex three-dimensional scaffold)로 조립하는 것을 더욱 포함하는 것을 특징으로 하는 방법.
- 제1항의 방법에 의해 제조된, 양막 내의 콜라겐이 천연 3차 및 4차 구조를 가지며, 양막이 무기질(無基質 substrate-free)인 것을 특징으로 하는 콜라겐 생구조물.
- 제1항의 방법에 의해 제조된, 양막이 무기질(無基質 substrate-free)이며, 콜라겐, 에라스틴 및 피브로넥틴을 포함하는 콜라겐 생구조물.
- 제1항의 방법에 의하여 제조된 콜라겐 생구조물.
- 제24항에 있어서, 상기 양막은 인간 양막인 것을 특징으로 하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항에 있어서, 상기 생구조물은 10에서 40 마이크론의 두께를 갖는 것을 특징으로 하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항에 있어서, 상기 생구조물은 항생물질, 호르몬, 성장 인자, 항-종양제, 항진균제, 항바이러스제, 통증 치료제, 항히스타민제, 항염증제, 항감염제, 상처 치유제, 상처 봉합체, 세포 유인제 및 스캐폴딩제로 구성된 군으로부터 선택된 하나 이상의 생분자들을 더욱 포함하는 것을 특징으로 하는 콜라겐 생구조물.
- 삭제
- 제29항에 있어서, 상기 콜라겐 생구조물은 몰 당 10,000그람 보다 작은 분자량을 가진 펩타이드, 펩타이드 의사체(peptidomimetic), 아미노산, 아미노산 유사체(analog), 폴리뉴클레오티드, 폴리뉴클레오티드 유사체, 뉴클레오티드, 뉴클레오티드 유사체, 유기 또는 무기 화합물 및 이들의 염, 에스터, 및 다른 약학적으로 허용 가능한 형태로 구성된 군으로부터 선택된 하나 이상의 소분자들을 더욱 포함하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항에 있어서, 상기 생구조물은 균일하고 합류 세포(confluent cell) 상태를 이루도록 군집된 세포를 더 포함하는 것을 특징으로 하는 콜라겐 생구조물.
- 제32항에 있어서, 상기 세포들은 인간 줄기세포 또는 인간 분화된 성인 세포들인 것을 특징으로 하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항에 있어서, 상기 생구조물은 하나 이상의 치료제를 더욱 포함하는 것을 특징으로 하는 콜라겐 생구조물.
- 제34항에 있어서, 상기 치료제는 호르몬, 펩타이드, 항생제, 항진균제 및 효소로 구성된 군으로부터 선택된 치료제인 것을 특징으로 하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항에 있어서, 상기 생구조물은 하나 이상의 하이드로겔 조성물을 더욱 포함하는 것을 특징으로 하는 콜라겐 생구조물.
- 제36항에 있어서, 상기 하이드로겔 조성물은 폴리비닐 알콜, 폴리에틸렌 글리콜, 히알루론산(hyaluronic acid), 덱스트란 및 이들의 유도체 또는 유사물질(analog)로 구성된 군으로부터 선택된 고분자를 포함하는 것을 특징으로 하는 콜라겐 생구조물.
- 제24항에서 제26항 중 어느 한 항의 콜라겐 생구조물을 포함하는 3차원 스캐폴드.
- 제38항에 있어서, 상기 스캐폴드는 튜브인 것을 특징으로 하는 3차원 스캐폴드.
- 제38항에 있어서, 상기 스캐폴드는 하나 이상의 하이드로겔 조성물을 더욱 포함하는 것을 특징으로 하는 3차원 스캐폴드.
- 제40항에 있어서, 상기 하이드로겔 조성물은 폴리비닐 알콜, 폴리에틸렌 글리콜, 히알루론산(hyaluronic acid), 덱스트란 및 이들의 유도체 또는 유사물질(analog)로 구성된 군으로부터 선택된 고분자를 포함하는 것을 특징으로 하는 3차원 스캐폴드.
- 제20항의 방법에 의하여 제조된 양막 래미네이트.
- 제24항에서 제26항 중 어느 한 항의 콜라겐 생구조물을 두 층 이상 포함하는 양막 래미네이트.
- 제24항에서 제26항 중 어느 한 항의 콜라겐 생구조물을 포함하는 양막 래미네이트.
- 제42항에 있어서, 상기 래미네이트는 하나 이상의 하이드로겔 조성물을 더욱 포함하는 양막 래미네이트.
- 제45항에 있어서, 상기 하이드로겔 조성물은 폴리비닐 알콜, 폴리에틸렌 글리콜, 히알루론산, 덱스트란 및 이들의 유도체 또는 유사물질(analog)로 구성된 군으로부터 선택된 고분자를 포함하는 것을 특징으로 하는 양막 래미네이트.
- 제24항에서 제26항 중 어느 한 항의 콜라겐 생구조물을 포함하는 수술 이식물(surgical graft).
- 수술 대상의 수술 자리에 직접 적용되는 것을 특징으로 하는, 수술 절차(surgical procedure)에서의 이용을 위한 제47항에 따른 수술 이식물.
- 제48항에 있어서, 상기 수술(surgical) 자리는 눈, 피부, 복부의 장막 표면, 흉강의 장막 표면, 장 심장막, 구강의 점액질 표면, 비강의 점액질 표면, 호흡기관 표면, 위장관 표면 및 비뇨생식기관 표면으로 구성된 군으로부터 선택된 것을 특징으로 하는 수술 이식물.
- 제48항에 있어서, 상기 수술 이식물은 수술 대상의 몸의 내부 자리에 적용하는 것을 특징으로 하는 수술 이식물.
- 제48항에 있어서, 상기 수술 이식물은 대상의 몸의 외부 자리에 적용하는 것을 특징으로 하는 수술 이식물.
- 제48항에 있어서, 상기 대상은 인간인 것을 특징으로 하는 수술 이식물.
- 개체(subject)의 질환 있는 눈 표면에 위치시켜지는 것을 특징으로 하는, 개체(subject)의 안과 질환 치료 또는 예방용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 제53항에 있어서, 상기 안과질환은 궤양(ulceration)/천공(perforation), 수포각막병증, 안 유피종(ocular dermoid)/종양, 1차 익상편(primary pterygium), 지속적 각막 상피 결함, 급성 및 만성 알칼리 화상들, 열 화상들, 홍체결여증(aniridia), 아토피성 각막염, 특발성 윤부 줄기 세포 결핍(idipathic limbal stem cell deficiency), 각막 판누스(pannus), 신혈관 신생, 류머티스성 각막 용해, 안 반흔성유천포창(cicatricial pemphigoid), 누수되는 여과 수포(leaking filtering bleb), 노출된 아메드 밸브관(exposed Ahmed valve tube), 차후 검구유착을 갖는 세라시아 봉와직염(Serratia cellulitis with subsequent symblepharon), 급성 및 만성 스티븐슨 존슨(Stevenson Johnson) 증후군으로 구성된 군으로부터 선택된 질환인 것을 특징으로 하는 콜라겐 생구조물.
- 안과 수술; 심혈관 수술; 치주 수술; 신경학적 수술, 치과수술 및 정형외과 수술로 구성된 군으로부터 선택된 수술 절차에서의 사용을 위한 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 개체(subject)의 비뇨기적 실금의 치료용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 개체와 접촉하여 치료제를 전달하는, 치료제 전달용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 제56항에 있어서, 상기 개체는 인간인 것을 특징으로 하는 콜라겐 생구조물.
- 제57항에 있어서, 상기 치료제는 항생물질, 항암제, 항세균제, 항바이러스제, 백신, 마취제, 진통제, 항 천식제, 항염증제, 항우울제, 항당뇨제, 항정신제, 중추신경계 자극제, 호르몬, 면역 억제제, 근육 이완제 및 프로스타그란딘으로 구성된 군으로부터 선택된 치료제인 것을 특징으로 하는 콜라겐 생구조물.
- 콜라겐 생구조물의 제조 시간에 콜라겐 생구조물의 수화를 포함하는 제24항 에서 제26항 중 어느 한 항의 콜라겐 생구조물을 이용하는 방법.
- 제60항에 있어서, 상기 생구조물의 수화는 살균된 식염수로 수화하는 것을 포함하는 방법.
- 제60항에 있어서, 상기 생구조물은 사용 전 적어도 2분간 수화하는 것을 특징으로 하는 방법.
- 살아 있는 세포를 양막 래미네이트 표면에 증식시키는 단계를 더욱 포함하는 것을 특징으로 하는 양막 래미네이트의 사용 방법.
- 제63항에 있어서, 상기 살아 있는 세포는 성인 조직 세포 및 줄기 세포로 구성된 군으로부터 선택된 방법.
- 제64항에 있어서, 상기 줄기 세포는 분화전능한(totipotent) 것을 특징으로 하는 방법.
- 제64항에 있어서, 상기 줄기 세포는 만능(pluripotent)인 것을 특징으로 하는 방법.
- 제64항에 있어서, 상기 줄기 세포는 조직 특이적인 것을 특징으로 하는 방법.
- 피부 질환과 접촉하는 것을 특징으로 하는, 개체 내 피부 질환의 치료 또는 예방용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 제68항에 있어서, 상기 피부 질환은 피부 손상, 주름, 세선(fine line), 얇은 피부, 감소된 피부 신축성, 거친 피부, 여드름 흉터, 미간 후로스(glabellar furros), 절개 흉터, 연 조직 결함, 선천적 피부 질환, 퇴행성 피부 질환, 콜라겐 Ⅶ 결함 및 태양 손상된 피부로 구성된 군으로부터 선택된 질환인 것을 특징으로 하는 콜라겐 생구조물.
- 제68항에 있어서, 상기 콜라겐 생구조물은 개체에 하나 이상의 치료제를 투여하기에 적합한 것임을 특징으로 하는 콜라겐 생구조물.
- 제70항에 있어서, 상기 하나 이상의 치료제는 비타민, 미네랄, 카테킨 기반 조제물 및 글루코사민으로 구성된 군으로부터 선택된 것을 특징으로 하는 콜라겐 생구조물.
- 상처와 접촉하는 것을 특징으로 하는, 개체 내 상처의 치료용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 제72항에 있어서, 상기 상처는 표피 상처, 피부 상처, 압력(pressure) 궤양, 만성 상처, 급성상처, 외부 상처, 내부 상처, 선천적 상처, 화상 상처, 외과 상처 및 상처 감염으로 이루어진 군으로부터 선택된 상처인 것을 특징으로 하는 콜라겐 생구조물.
- 화상 부위와 접촉하는 것을 특징으로 하는, 개체 내 화상의 치료용 제24항에서 제26항 중 어느 한 항에 따른 콜라겐 생구조물.
- 제74항에 있어서, 상기 화상은 1도 화상, 2도 화상, 3도 화상, 감염된 화상 상처 및 화상 상처 농가진으로 이루어진 군으로부터 선택된 것을 특징으로 하는 콜라겐 생구조물.
- 제68항에 있어서, 상기 개체는 인간인 것을 특징으로 하는 콜라겐 생구조물.
- 제43항에 있어서, 상기 래미네이트는 하나 이상의 하이드로겔 조성물을 더욱 포함하는 것을 특징으로 하는 양막 래미네이트.
- 제44항에 있어서, 상기 래미네이트는 하나 이상의 하이드로겔 조성물을 더욱 포함하는 것을 특징으로 하는 양막 래미네이트.
- 제57항에 있어서, 상기 개체는 인간인 것을 특징으로 하는 콜라겐 생구조물.
- 제72항에 있어서, 상기 개체는 인간인 것을 특징으로 하는 콜라겐 생구조물.
- 제74항에 있어서, 상기 개체는 인간인 것을 특징으로 하는 콜라겐 생구조물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/106,653 | 2002-03-26 | ||
US10/106,653 US20030187515A1 (en) | 2002-03-26 | 2002-03-26 | Collagen biofabric and methods of preparing and using the collagen biofabric |
PCT/US2003/009304 WO2003082201A2 (en) | 2002-03-26 | 2003-03-26 | Collagen biofabric and methods of preparation and use therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050002906A KR20050002906A (ko) | 2005-01-10 |
KR100999247B1 true KR100999247B1 (ko) | 2010-12-07 |
Family
ID=28452543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047015383A KR100999247B1 (ko) | 2002-03-26 | 2003-03-26 | 콜라겐 생구조물 및 그 제조방법 및 용도 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030187515A1 (ko) |
EP (4) | EP2700309B1 (ko) |
JP (3) | JP4615223B2 (ko) |
KR (1) | KR100999247B1 (ko) |
CN (1) | CN1791331A (ko) |
AU (3) | AU2003226018B2 (ko) |
CA (1) | CA2479903C (ko) |
DK (2) | DK2700309T3 (ko) |
ES (2) | ES2526088T3 (ko) |
HK (1) | HK1085384A1 (ko) |
IL (2) | IL164220A0 (ko) |
MX (1) | MXPA04009188A (ko) |
NZ (1) | NZ535799A (ko) |
PT (1) | PT2702871T (ko) |
WO (1) | WO2003082201A2 (ko) |
ZA (1) | ZA200407650B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140023282A (ko) * | 2011-02-14 | 2014-02-26 | 미메딕스 그룹 인크. | 가교제로 변형된 조직 이식편 및 그것의 제조 및 사용 방법 |
KR20150138157A (ko) * | 2013-01-09 | 2015-12-09 | 아이에스이 프로페셔널 테스팅 앤드 컨설팅 서비시즈, 인코퍼레이티드 | 비-포유류 조직으로부터의 세포제거된 생체재료 |
Families Citing this family (260)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL156303A0 (en) * | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
KR100973615B1 (ko) * | 2001-02-14 | 2010-08-02 | 안트로제네시스 코포레이션 | 산후 포유류의 태반, 이의 용도 및 태반 줄기세포 |
CA2856986C (en) * | 2001-02-14 | 2019-08-13 | Anthrogenesis Corporation | Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders |
AU2002258734A1 (en) * | 2001-04-13 | 2002-10-28 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
JP3888573B2 (ja) * | 2001-06-29 | 2007-03-07 | 富士電機ホールディングス株式会社 | ハンダ組成物 |
MXPA04009996A (es) * | 2002-04-12 | 2005-07-01 | Celgene Corp | Metodos para la identificacion de moduladores de la angiogenesis, compuestos descubiertos por los mismos, y metodos de tratamiento usando los compuestos. |
MXPA04009997A (es) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas. |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
BR0316695A (pt) | 2002-11-26 | 2005-10-18 | Anthrogenesis Corp | Unidade citoterapêutica, kit para tratamento, método de tratamento de uma enfermidade, biblioteca de unidades citoterapêuticas e método de tratamento de um paciente |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
GB0322145D0 (en) * | 2003-09-22 | 2003-10-22 | Howmedica Internat S De R L | Apparatus for use in the regeneration of structured human tissue |
ES2403357T3 (es) | 2003-12-11 | 2013-05-17 | Isto Technologies Inc. | Sistema de cartílago particulado |
US7775965B2 (en) * | 2004-03-09 | 2010-08-17 | The Board Of Regents Of The University Of Oklahoma | Decellularized grafts from umbilical cord vessels and process for preparing and using same |
US20050287223A1 (en) * | 2004-06-23 | 2005-12-29 | Peyman Gholam A | Use of amniotic membrane as biocompatible devices |
US8802651B2 (en) * | 2004-06-30 | 2014-08-12 | Abbott Medical Optics Inc. | Hyaluronic acid in the enhancement of lens regeneration |
US8512730B2 (en) | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
US20060190017A1 (en) * | 2004-11-19 | 2006-08-24 | Cyr John S | Fibrin sealants and platelet concentrates applied to effect hemostasis at the interface of an implantable medical device with body tissue |
JP2006176499A (ja) * | 2004-11-25 | 2006-07-06 | Nippon Seibutsu Seizai:Kk | 眼疾患治療剤 |
US20070015685A1 (en) * | 2005-04-04 | 2007-01-18 | Naomi Balaban | Bone cement compositions and the like comprising an RNAIII-inhibiting peptide |
WO2006129673A1 (ja) * | 2005-05-30 | 2006-12-07 | Arblast Co., Ltd. | 組織再建用材料及びその使用 |
US20070038298A1 (en) * | 2005-06-30 | 2007-02-15 | Sulner Joseph W | Repair of tympanic membrane using placenta derived collagen biofabric |
WO2007009061A2 (en) * | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
EP1919500A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
GB0514567D0 (en) * | 2005-07-15 | 2005-08-24 | Univ Nottingham | Surgical membrane |
US7837673B2 (en) | 2005-08-08 | 2010-11-23 | Innovative Therapies, Inc. | Wound irrigation device |
EP1932549B1 (en) * | 2005-08-26 | 2016-12-28 | AMNOS Co., Ltd. | Dried amnion and method for drying treatment of amnion |
WO2007025290A2 (en) | 2005-08-26 | 2007-03-01 | Isto Technologies, Inc. | Implants and methods for repair, replacement and treatment of joint disease |
JP4977345B2 (ja) * | 2005-08-26 | 2012-07-18 | 国立大学法人富山大学 | 乾燥羊膜及び羊膜の乾燥処理方法 |
US20070074980A1 (en) * | 2005-09-02 | 2007-04-05 | Bankoski Brian R | Implant rehydration packages and methods of use |
AU2006295080A1 (en) * | 2005-09-21 | 2007-04-05 | Medtronic, Inc. | Composite heart valve apparatus manufactured using techniques involving laser machining of tissue |
EP1933852B1 (en) | 2005-09-27 | 2018-12-19 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
ZA200803929B (en) * | 2005-10-13 | 2009-08-26 | Anthrogenesis Corp | Production of oligodendrocytes from placenta-derived stem cells |
EP1957633B1 (en) * | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8268361B2 (en) * | 2005-10-26 | 2012-09-18 | Ahlfors Jan-Eric W | Acellular bioabsorbable tissue regeneration matrices |
EP1974013A2 (en) | 2005-12-29 | 2008-10-01 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
CA2633775A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
ES2703502T3 (es) | 2005-12-29 | 2019-03-11 | Celularity Inc | Poblaciones de células madre placentarias |
MX2008015645A (es) * | 2006-06-09 | 2009-02-06 | Anthrogenesis Corp | Nicho placentario y uso de este para cultivar celulas primordiales. |
US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
US20080131522A1 (en) * | 2006-10-03 | 2008-06-05 | Qing Liu | Use of placental biomaterial for ocular surgery |
WO2008060377A2 (en) | 2006-10-04 | 2008-05-22 | Anthrogenesis Corporation | Placental or umbilical cord tissue compositions |
NZ612094A (en) * | 2006-10-06 | 2015-02-27 | Anthrogenesis Corp | Native (telopeptide) placental collagen compositions |
AU2013203210B2 (en) * | 2006-10-06 | 2015-05-28 | Celularity Inc. | Native (telopeptide) placental collagen compositions |
NZ576194A (en) | 2006-10-23 | 2012-02-24 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
CA2674524C (en) * | 2006-12-22 | 2014-05-20 | Laboratoire Medidom S.A. | In situ system for intra-articular chondral and osseous tissue repair |
KR100795708B1 (ko) * | 2006-12-26 | 2008-01-17 | 주식회사 알앤엘바이오 | 인간 양막 상피세포 유래 성체 줄기세포의 분리 및 배양방법 |
CA2677679A1 (en) | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
RS52921B (en) | 2007-02-12 | 2014-02-28 | Anthrogenesis Corporation | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL CELL CELLS |
US20090012629A1 (en) | 2007-04-12 | 2009-01-08 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
EP2178575A2 (en) * | 2007-04-16 | 2010-04-28 | Tissue Science Laboratories PLC | Methods and compositions for tissue regeneration |
TWM322542U (en) * | 2007-05-23 | 2007-11-21 | Universal Scient Ind Co Ltd | Testing machine |
DE102007037051A1 (de) * | 2007-07-24 | 2009-01-29 | Aesculap Ag | Flächiges Implantat |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
EP3689421A1 (en) | 2007-09-07 | 2020-08-05 | MiMedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
US20090069843A1 (en) * | 2007-09-10 | 2009-03-12 | Agnew Charles W | Fistula plugs including a hydration resistant component |
MX2010003217A (es) * | 2007-09-26 | 2010-07-30 | Celgene Cellular Therapeutics | Celulas angiogenicas de perfundido de placenta humana. |
KR20180107320A (ko) | 2007-09-28 | 2018-10-01 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
KR20210056449A (ko) * | 2007-11-07 | 2021-05-18 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
RU2461622C2 (ru) * | 2007-11-28 | 2012-09-20 | Огенодженесис, Инк. | Биоинженерный конструкт для имплантации ткани и способ изготовления названного биоинженерного конструкта (варианты) |
US20090163990A1 (en) * | 2007-12-19 | 2009-06-25 | Chunlin Yang | Decellularized omentum matrix and uses thereof |
KR101572634B1 (ko) | 2008-04-04 | 2015-12-01 | 포사이트 비젼4, 인크. | 통증 관리 및 시력을 위한 치료 장치 |
EP2288376B1 (en) | 2008-04-18 | 2016-01-13 | Collplant Ltd. | Methods of generating and using procollagen |
US9480549B2 (en) | 2008-04-25 | 2016-11-01 | Allosource | Multi-layer tissue patches |
AU2009240564A1 (en) * | 2008-04-25 | 2009-10-29 | Allosource | Anti-adhesion barrier wound dressing comprising processed amniotic tissue and method of use |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
WO2010014021A1 (en) * | 2008-07-30 | 2010-02-04 | Mesynthes Limited | Tissue scaffolds derived from forestomach extracellular matrix |
US20100080840A1 (en) * | 2008-07-31 | 2010-04-01 | Michael Cho | Hybrid superporous hydrogel scaffold for cornea regeneration |
WO2010021715A1 (en) * | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
PE20110400A1 (es) | 2008-08-20 | 2011-06-22 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas |
JP2012500792A (ja) | 2008-08-22 | 2012-01-12 | アンスロジェネシス コーポレーション | 胎盤細胞集団による骨欠損の治療のための方法および組成物 |
US8858698B2 (en) * | 2008-09-05 | 2014-10-14 | Mentor Worldwide Llc | Acellular matrix glue |
US7927414B2 (en) * | 2008-09-05 | 2011-04-19 | Ethicon, Inc. | Method of manufacturing acellular matrix glue |
NZ602455A (en) | 2008-11-19 | 2014-03-28 | Anthrogenesis Corp | Amnion derived adherent cells |
EP2375907B1 (en) * | 2008-11-21 | 2019-02-27 | Celularity, Inc. | Treatment of diseases, disorders or conditions of the lung using placental cells |
EP2403438B1 (en) * | 2009-03-04 | 2021-04-21 | Peytant Solutions, Inc. | Stents modified with material comprising amnion tissue and corresponding processes |
PL2411506T3 (pl) | 2009-03-25 | 2019-07-31 | Celularity, Inc. | Hamowanie nowotworu z użyciem ludzkich pochodzących z łożyska komórek nk pośrednich i związki immunomodulujące |
US9039783B2 (en) * | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US20100323446A1 (en) | 2009-06-05 | 2010-12-23 | Jill Renee Barnett | Method of collecting placental cells |
MX2012000110A (es) | 2009-07-02 | 2012-04-02 | Anthrogenesis Corp | Metodo para producir eritrocitos sin celulas alimetadoras. |
KR101103571B1 (ko) * | 2009-09-23 | 2012-01-09 | 한림대학교 산학협력단 | 피부조직 재생용 구조체 및 이를 이용한 인공피부 |
US20130066283A1 (en) | 2009-10-23 | 2013-03-14 | Nexisvision, Inc. | Corneal Denervation for Treatment of Ocular Pain |
EP2490620A4 (en) | 2009-10-23 | 2017-03-22 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
WO2011074208A1 (ja) * | 2009-12-18 | 2011-06-23 | 国立大学法人東北大学 | 皮膚真皮又は羊膜透明化による角膜移植材料調製法 |
JP2013518108A (ja) | 2010-01-26 | 2013-05-20 | アントフロゲネシス コーポレーション | 胎盤幹細胞を用いる骨関連癌の治療 |
WO2011103446A1 (en) * | 2010-02-18 | 2011-08-25 | Osiris Therapeutics, Inc. | Immunocompatible chorionic membrane products |
TW201902496A (zh) | 2010-04-07 | 2019-01-16 | 美商安瑟吉納西斯公司 | 利用胎盤幹細胞之血管新生 |
CA2795401A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
WO2012003377A2 (en) * | 2010-06-30 | 2012-01-05 | Tissuetech, Inc. | Methods of preparing chorion tissue and products derived therefrom |
CA2804592C (en) * | 2010-07-08 | 2019-10-29 | Lifecell Corporation | Method for shaping tissue matrices |
EP3358007A1 (en) | 2010-07-13 | 2018-08-08 | Celularity, Inc. | Methods of generating natural killer cells |
US20120035743A1 (en) * | 2010-08-03 | 2012-02-09 | AFcell Medical | Amnion and chorion constructs and uses thereof in minimally invasive surgeries |
US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
US9433490B2 (en) | 2010-12-22 | 2016-09-06 | University Of Florida Research Foundation, Inc. | Multilayered implant materials derived from amniotic membrane, methods of making the multilayered implant materials, and method of using multilayered implant materials |
AR084753A1 (es) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp) |
AR084754A1 (es) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso |
WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
KR20140107103A (ko) | 2011-02-14 | 2014-09-04 | 미메딕스 그룹 인크. | 마이크로화된 태반 조직 조성물 및 이의 제조 및 사용 방법 |
AU2012217975B2 (en) * | 2011-02-14 | 2015-11-19 | Mimedx Group Inc. | Micronized placental tissue compositions and methods for making and using the same |
US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
WO2012166844A2 (en) | 2011-06-01 | 2012-12-06 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
ES2822301T3 (es) | 2011-06-10 | 2021-04-30 | Tissuetech Inc | Métodos de procesamiento de tejidos de soporte fetal |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
US20130136773A1 (en) * | 2011-09-30 | 2013-05-30 | NuTech Spine, Inc. | Expandable Placental Membrane and Methods of Making and Storing Same |
US10517902B2 (en) * | 2011-09-30 | 2019-12-31 | Prime Merger Sub, Llc | Expandable amnion membrane for treating non-healing wounds |
US9585983B1 (en) * | 2011-10-12 | 2017-03-07 | BioDlogics, LLC | Wound covering and method of preparation |
WO2013082412A1 (en) | 2011-12-02 | 2013-06-06 | Mimedx Group, Inc. | Placental tissue grafts produced by chemical dehydration/freeze-drying and methods for making and using same |
US9162011B2 (en) | 2011-12-19 | 2015-10-20 | Allosource | Flowable matrix compositions and methods |
WO2013095830A1 (en) | 2011-12-22 | 2013-06-27 | Mimedx Group Inc. | Cross-linked dehydrated placental tissue grafts and methods for making and using the same |
JP2015510391A (ja) * | 2011-12-23 | 2015-04-09 | アントフロゲネシス コーポレーション | 脱細胞されて再構築された胎盤の脈管足場を含むオルガノイド |
US9416410B2 (en) * | 2012-02-14 | 2016-08-16 | Genetics Development Corporation | Cutoff point delta Ct. method for HER2 PCR testing in breast cancer |
US9575054B2 (en) * | 2012-02-23 | 2017-02-21 | Anthrogenesis Corporation | Identification of antitumor compounds using placenta |
US10071184B2 (en) * | 2012-02-29 | 2018-09-11 | Collagen Matrix, Inc. | Collagen-coated tissue-based membranes |
US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
US20180126033A9 (en) | 2012-03-14 | 2018-05-10 | MAM Holdings of West Florida, L.L.C. | Collagen compositions and uses for biomaterial implants |
US10576037B2 (en) * | 2012-03-14 | 2020-03-03 | MAM Holdings of West Florida, L.L.C. | Compositions comprising placental collagen for use in wound healing |
KR101404089B1 (ko) * | 2012-04-02 | 2014-06-05 | 원광대학교산학협력단 | 양막 추출물을 함유하는 이중층 하이드로겔 습윤드레싱 및 그 제조방법 |
WO2014028453A2 (en) | 2012-08-13 | 2014-02-20 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
US11338063B2 (en) * | 2012-08-15 | 2022-05-24 | Mimedx Group, Inc. | Placental tissue grafts modified with a cross-linking agent and methods of making and using the same |
EP2884944B1 (en) * | 2012-08-15 | 2020-10-07 | MiMedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
MX2015002711A (es) * | 2012-09-04 | 2015-06-05 | Anthrogenesis Corp | Metodos de generacion de tejidos. |
KR20150059754A (ko) | 2012-09-04 | 2015-06-02 | 안트로제네시스 코포레이션 | 조직 생성 방법 |
ES2756332T3 (es) | 2012-09-10 | 2020-04-27 | Univ Wake Forest Health Sciences | Membrana amniótica y su uso en cicatrización de heridas y construcciones de ingeniería tisular |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US9155799B2 (en) | 2012-11-19 | 2015-10-13 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US8940684B2 (en) | 2012-11-19 | 2015-01-27 | Mimedx Group, Inc. | Cross-linked collagen comprising an antifungal agent |
US8946163B2 (en) | 2012-11-19 | 2015-02-03 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
JP2016501245A (ja) * | 2012-12-07 | 2016-01-18 | アントフロゲネシス コーポレーション | 胎盤細胞外マトリクスを使用する口腔病変の治療 |
CA2895106C (en) | 2012-12-14 | 2023-01-24 | Anthrogenesis Corporation | Anoikis resistant placental stem cells and uses thereof |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
CN103006349A (zh) * | 2012-12-26 | 2013-04-03 | 天津市赛宁生物工程技术有限公司 | 体外培养的组织工程血管 |
US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9655948B1 (en) | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9662355B2 (en) | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
US10905800B1 (en) | 2013-01-29 | 2021-02-02 | BioDlogics, LLC | Ocular covering and method of use |
EP2951289B1 (en) * | 2013-01-30 | 2019-10-02 | Nutech Medical, Inc. | Placental membrane preparation and methods of making and using same |
CN103127549A (zh) * | 2013-02-01 | 2013-06-05 | 中山大学中山眼科中心 | 一种脱细胞睑板及其制备方法 |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9498327B1 (en) | 2013-03-05 | 2016-11-22 | Biodlogics Llc | Repair of tympanic membrane using human birth tissue material |
US9789138B1 (en) | 2013-03-06 | 2017-10-17 | BioDlogics, LLC | Neural repair construct and method of use |
US9770472B1 (en) | 2013-03-08 | 2017-09-26 | Brahm Holdings, Llc | Organ jacket and methods of use |
AU2014248873B2 (en) | 2013-03-13 | 2017-03-23 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
US9855301B1 (en) | 2013-03-13 | 2018-01-02 | Biodlogics Llc | Human birth tissue laminate and methods of use |
DK2970883T3 (da) | 2013-03-14 | 2021-08-09 | Celularity Inc | Forbedrede placenta stamceller og bruge deraf |
US10029030B2 (en) * | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
CA2901841A1 (en) | 2013-03-15 | 2014-09-18 | NuTech Medical, Inc. | Preparations derived from placental materials and methods of making and using same |
CA2899713C (en) | 2013-03-15 | 2022-07-19 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
NO2975611T3 (ko) * | 2013-03-15 | 2018-06-09 | ||
US9795638B1 (en) | 2013-03-16 | 2017-10-24 | BioDlogics, LLC | Cardiothoracic construct and methods of use |
CN104083803B (zh) * | 2013-04-01 | 2016-04-27 | 陕西佰傲再生医学有限公司 | 一种用于眼表修复的生物膜及其制备方法 |
US10335433B2 (en) | 2013-04-10 | 2019-07-02 | Mimedx Group, Inc. | NDGA polymers and metal complexes thereof |
WO2014189835A2 (en) * | 2013-05-20 | 2014-11-27 | Yale University | Anti-thrombogenic grafts |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
WO2014209856A1 (en) | 2013-06-24 | 2014-12-31 | Anthrogenesis Corporation | Extracellular matrix composition beads for cell culture |
EP3014345A2 (en) | 2013-06-26 | 2016-05-04 | Nexisvision, Inc. | Contact lenses for refractive correction |
WO2015031681A1 (en) | 2013-08-30 | 2015-03-05 | Mimedx Group, Inc. | Micronized placental compositions comprising a chelator |
EP2857350A1 (en) * | 2013-09-10 | 2015-04-08 | ESPCI Innov | Use of nanoparticles for gluing gels |
WO2015085232A1 (en) | 2013-12-06 | 2015-06-11 | Allosource | Method of drying sheets of tissue |
US10052351B2 (en) | 2014-01-17 | 2018-08-21 | Mimedx Group, Inc. | Method for inducing angiogenesis |
WO2015120405A1 (en) * | 2014-02-07 | 2015-08-13 | Amniolife Corporation | Patterned tissue membranes and methods and system for their preparation |
US10894066B2 (en) | 2014-03-06 | 2021-01-19 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
US9132156B1 (en) * | 2014-06-15 | 2015-09-15 | Amnio Technology Llc | Acellular amnion derived therapeutic compositions |
US9801910B2 (en) * | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
CN103861151B (zh) * | 2014-03-27 | 2016-03-30 | 成都青山利康药业有限公司 | 一种脱细胞胎盘基质材料的制备方法 |
CA2948126A1 (en) * | 2014-05-07 | 2015-11-12 | Osiris Therapeutics, Inc. | Therapeutic placental compositions, methods of making and methods of use |
JP2017514879A (ja) * | 2014-05-07 | 2017-06-08 | オシリス セラピューティクス,インコーポレイテッド | 免疫適合性のある羊膜生成物 |
US11083758B2 (en) | 2014-05-14 | 2021-08-10 | Prime Merger Sub, Llc | Placental membrane preparations and methods of making and using same for regenerating cartilage and spinal intervertebral discs |
AU2015267148B2 (en) | 2014-05-28 | 2021-07-29 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
TW201603818A (zh) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | 組成物及方法 |
US10363278B2 (en) | 2014-06-15 | 2019-07-30 | Amnio Technology Llc | Frozen therapeutic dose and package |
CN105311057A (zh) * | 2014-07-29 | 2016-02-10 | 黄玲惠 | 含胶原蛋白与透明质酸的细胞组织胶体 |
JP7099822B2 (ja) * | 2014-08-28 | 2022-07-12 | ミメディクス グループ インコーポレイテッド | コラーゲンで強化した組織移植片 |
US12083245B2 (en) | 2014-10-02 | 2024-09-10 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
AU2015330962B2 (en) * | 2014-10-10 | 2017-09-21 | Orthocell Limited | Sutureless repair of soft tissue |
CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
US10265438B1 (en) | 2014-11-03 | 2019-04-23 | BioDlogics, LLC | Methods and compositions for the repair and replacement of connective tissue |
US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
US20180021378A1 (en) | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
WO2016111899A1 (en) | 2015-01-05 | 2016-07-14 | Petrucci Gary M | Methods and materials for treating lung disorders |
US10736990B2 (en) * | 2015-02-11 | 2020-08-11 | Mimedx Group, Inc. | Collagen and micronized placental tissue compositions and methods of making and using the same |
TW201642914A (zh) | 2015-02-23 | 2016-12-16 | 組織科技股份有限公司 | 用於治療眼部疾病及失調的裝置及方法 |
CN107635567A (zh) * | 2015-04-17 | 2018-01-26 | 加利福利亚大学董事会 | 用于细胞输送、细胞培养和炎症预防的脱细胞化的人羊膜 |
CN104826166B (zh) * | 2015-05-06 | 2017-06-06 | 广州优适清生物科技有限公司 | 一种用于青光眼治疗的生物膜及其制备方法 |
TWI720984B (zh) | 2015-05-20 | 2021-03-11 | 美商帝聖工業公司 | 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法 |
CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
CN105169493B (zh) * | 2015-07-13 | 2018-02-27 | 江南大学 | 一种人工异种皮肤的制备方法 |
US10517903B2 (en) | 2015-09-14 | 2019-12-31 | Amnio Technology Llc | Amnion derived therapeutic composition and process of making same |
SG10201912572VA (en) | 2015-09-15 | 2020-02-27 | Celularity Inc | Treatment of diabetic peripheral neuropathy using placental cells |
EP3352771B1 (en) | 2015-09-23 | 2021-03-24 | Osiris Therapeutics, Inc. | Umbilical tissue compositions and methods of use |
US20180318359A1 (en) * | 2015-09-29 | 2018-11-08 | Anicell Biotech, Llc | Methods and articles of manufacture for the treatment of animals |
AU2016344019B2 (en) | 2015-10-30 | 2021-07-15 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Suture sleeve patch and methods of delivery within an existing arthroscopic workflow |
US20170136070A1 (en) * | 2015-11-18 | 2017-05-18 | Dregalla Patent Holdco, LLC | Acellular Regenerative Products and Methods of Their Manufacture |
CA3009178A1 (en) | 2015-12-23 | 2017-06-29 | Lifenet Health | Decellularized placental membrane and methods of preparing and use thereof |
TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
US11484401B2 (en) | 2016-02-01 | 2022-11-01 | Medos International Sarl | Tissue augmentation scaffolds for use in soft tissue fixation repair |
US10702260B2 (en) | 2016-02-01 | 2020-07-07 | Medos International Sàrl | Soft tissue fixation repair methods using tissue augmentation scaffolds |
WO2017136557A1 (en) | 2016-02-05 | 2017-08-10 | Petrucci Gary M | Methods and materials for treating nerve injuries and neurological disorders |
EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
CN105833353B (zh) * | 2016-05-09 | 2018-04-20 | 拜欧迪赛尔(北京)生物科技有限公司 | 一种生物工程脱细胞真皮基质的制备及用途 |
WO2018039294A1 (en) | 2016-08-24 | 2018-03-01 | Arthrex, Inc. | Tissue use for repair of injury |
IL266381B2 (en) * | 2016-11-02 | 2024-04-01 | Axogen Corp | Dragonfly embroidery implants, methods for their preparation, and their use |
CN106390195B (zh) * | 2016-11-16 | 2019-08-23 | 四川大学 | 一种胶原膜的改性方法 |
CN110062764B (zh) | 2016-12-05 | 2024-07-02 | 儿童医院医学中心 | 结肠类器官及其制备和使用方法 |
JP2020512970A (ja) | 2016-12-05 | 2020-04-30 | セルラリティ インコーポレイテッド | 胎盤接着性細胞を使用するリンパ浮腫および関連する状態の処置 |
CN108210995A (zh) * | 2016-12-14 | 2018-06-29 | 成都青山利康药业有限公司 | 一种新型的复合生物组织修复材料及其制备方法和用途 |
US11299630B2 (en) | 2017-01-26 | 2022-04-12 | 3Dbiofibr Inc. | Templated assembly of collagen fibers and uses thereof |
US10772986B2 (en) | 2017-01-26 | 2020-09-15 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
WO2018141075A1 (es) * | 2017-02-03 | 2018-08-09 | Biocellix Spa | Matriz o membrana de colágeno con propiedades antimicrobianas |
CN107137768B (zh) * | 2017-04-12 | 2020-07-07 | 苏州诺普再生医学有限公司 | 一种脱细胞羊膜粉的制备方法 |
JP7031138B2 (ja) | 2017-05-11 | 2022-03-08 | 株式会社リコー | 脱細胞化組織の製造方法、及び脱細胞化組織の製造装置 |
CN107233144A (zh) * | 2017-05-31 | 2017-10-10 | 中山大学中山眼科中心 | 去细胞角膜基质透镜在治疗眼科疾病中的应用 |
US10478531B2 (en) | 2017-06-22 | 2019-11-19 | Gary M. Petrucci | Methods and materials for treating blood vessels |
CN109481737B (zh) * | 2017-09-12 | 2021-07-06 | 中国人民解放军第三军医大学第一附属医院 | 一种仿生双层敷料及其制备方法 |
US10251917B1 (en) | 2017-09-19 | 2019-04-09 | Gary M. Petrucci | Methods and materials for treating tumors |
CA3077325A1 (en) | 2017-09-28 | 2019-04-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
WO2019099503A1 (en) | 2017-11-14 | 2019-05-23 | Cook Biotech Incorporated | Preserved tissue products and related methods |
CN108051509B (zh) * | 2017-11-21 | 2020-06-23 | 陈溉 | 一种治疗褥疮的药物的特征图谱检测方法及其应用 |
CN107929811A (zh) * | 2017-12-15 | 2018-04-20 | 厦门大学 | 一种组织工程角膜 |
WO2019165320A1 (en) | 2018-02-22 | 2019-08-29 | Celularity, Inc. | Post partum tissue-derived induced pluripotent stem cells and uses thereof |
US11602548B1 (en) | 2018-02-26 | 2023-03-14 | Convatec, Inc | Fibrous birth tissue composition and method of use |
CN109065670B (zh) * | 2018-08-08 | 2019-12-20 | 长春长光宇航复合材料有限公司 | 碳纤维复合材料网格蒙皮太阳能电池阵基板的制备方法 |
SG11202105213XA (en) | 2018-11-30 | 2021-06-29 | Celularity Inc | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds |
CN109557107A (zh) * | 2018-12-29 | 2019-04-02 | 南工大溧阳新材料研发中心有限公司 | 一种不锈钢/碳钢复合材料的探伤检测方法 |
US11511017B2 (en) | 2019-03-12 | 2022-11-29 | Arthrex, Inc. | Ligament reconstruction |
WO2020252464A1 (en) | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
WO2021016621A1 (en) | 2019-07-25 | 2021-01-28 | Celularity Inc. | Populations of natural killer cells comprising a cd38 chimeric antigen receptor |
US20230355759A1 (en) | 2019-07-31 | 2023-11-09 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
CN110404119B (zh) * | 2019-08-29 | 2023-04-07 | 上海越增生物科技有限公司 | 羊膜组织工程去免疫原皮肤支架的制备方法 |
WO2021113849A1 (en) | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
WO2021155312A1 (en) | 2020-01-29 | 2021-08-05 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
US20210244845A1 (en) * | 2020-02-10 | 2021-08-12 | Leslie MARCELIN | Method Of Processing Amnion To Form A Suture |
US20240216580A1 (en) | 2020-02-14 | 2024-07-04 | Kheiros Pater Inovação S.A. | Method for producing decellularized biomaterial, decellularized biomaterial and use thereof |
EP4125749A4 (en) * | 2020-04-03 | 2024-05-08 | BioTissue Holdings Inc. | METHOD OF USING UMBILICAL CORD PRODUCTS FOR THE TREATMENT OF OCULAR SURFACE DISEASES |
US20230210909A1 (en) | 2020-05-08 | 2023-07-06 | Celularity Inc. | Placenta-derived adherent (pda) stem cell for the treatment of adults with sars-cov-2 related acute respiratory failure and ards (covid-19) |
TW202233828A (zh) | 2020-11-12 | 2022-09-01 | 日商Adeka股份有限公司 | 去細胞化組織組成物 |
CN112641999B (zh) * | 2020-12-04 | 2022-10-04 | 陕西佰傲再生医学有限公司 | 一种铺膜设备及其应用 |
KR20230118861A (ko) * | 2020-12-11 | 2023-08-14 | 오스테오지닉스 바이오메디칼, 인크. | 다중-층 콜라겐-기반 막 |
AU2022257116A1 (en) * | 2021-04-13 | 2023-10-19 | Celularity Inc. | Multi-layer amniotic tissue grafts and uses thereof |
WO2023278628A1 (en) | 2021-06-29 | 2023-01-05 | Celularity Inc. | Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml |
WO2023010123A1 (en) | 2021-07-29 | 2023-02-02 | Celularity Inc. | Placenta-dervied nk cells as a senolytic for therapeutic and other uses |
CN114028618A (zh) * | 2021-10-25 | 2022-02-11 | 广东普洛宇飞生物科技有限公司 | 一种基于羊膜基底膜的生物材料及其制备方法和应用 |
WO2023137344A1 (en) | 2022-01-11 | 2023-07-20 | Celularity Inc. | Cleavage resistant cd16 constructs and uses thereof |
CN115054730B (zh) * | 2022-06-14 | 2023-08-18 | 健诺维(成都)生物科技有限公司 | 一种羊膜新材料及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3157524A (en) | 1960-10-25 | 1964-11-17 | Ethicon Inc | Preparation of collagen sponge |
US3800792A (en) | 1972-04-17 | 1974-04-02 | Johnson & Johnson | Laminated collagen film dressing |
DE2416313C3 (de) | 1974-04-04 | 1978-11-23 | Roland 8731 Euerdorf Satzinger | Sicherheitseinrichtung für die Insassen von Fahrzeugen, insbesondere Kraftfahrzeugen |
US4060081A (en) * | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
DE2943520C2 (de) | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Verfahren zur Herstellung von Kollagenschwamm für medizinische oder kosmetische Zwecke |
US4446234A (en) * | 1981-10-23 | 1984-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Vitro cellular interaction with amnion membrane substrate |
US4973493A (en) * | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US4883618A (en) | 1983-02-02 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Absorbable nerve repair device and method |
US4837285A (en) | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
US4778467A (en) | 1984-04-25 | 1988-10-18 | The University Of Utah | Prostheses and methods for promoting nerve regeneration and for inhibiting the formation of neuromas |
IL78950A (en) * | 1985-06-06 | 1991-12-15 | Univ Jefferson | Coating for prosthetic devices |
JPS63260549A (ja) * | 1987-04-17 | 1988-10-27 | 石川 統一 | 補綴材料およびその製造方法 |
WO1988008305A1 (en) | 1987-04-28 | 1988-11-03 | The Regents Of The University Of California | Method and apparatus for preparing composite skin replacement |
US5036056A (en) * | 1987-07-08 | 1991-07-30 | Martin Kludas | Methods for treating damaged corneal, uterine, or cartilage tissue |
GB8803697D0 (en) * | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
US5116620A (en) * | 1989-11-21 | 1992-05-26 | Bruce A. Barber | Antimicrobial wound dressing |
US5308627A (en) | 1990-08-07 | 1994-05-03 | Umbdenstock Jr Anthony J | Nutritional supplement for optimizing cellular health |
US5198465A (en) | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
EP0534152B1 (en) | 1991-09-26 | 1996-11-06 | United States Surgical Corporation | Nerve repair device |
US5418875A (en) | 1992-09-04 | 1995-05-23 | Honda Tsushin Kogyo Co., Ltd. | Adapter for optical connector having float-type sleeve holder and panel fitting for mounting the same |
US6124259A (en) * | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
JP3542170B2 (ja) * | 1993-08-06 | 2004-07-14 | 株式会社アムニオテック | 医用材料及びその製造方法 |
GB9400163D0 (en) | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
IL112580A0 (en) * | 1994-02-24 | 1995-05-26 | Res Dev Foundation | Amniotic membrane graft of wrap to prevent adhesions or bleeding of internal organs |
US6203755B1 (en) * | 1994-03-04 | 2001-03-20 | St. Jude Medical, Inc. | Electron beam sterilization of biological tissues |
EP1452153A1 (en) * | 1994-03-14 | 2004-09-01 | Cryolife, Inc | Treated tissue for implantation and preparation methods |
JP2905718B2 (ja) * | 1995-03-31 | 1999-06-14 | 東洋紡績株式会社 | 医用材料およびその製造方法 |
US5723010A (en) | 1995-03-31 | 1998-03-03 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
JPH09122227A (ja) | 1995-10-31 | 1997-05-13 | Bio Eng Lab:Kk | 医用材料およびその製造方法 |
JP3476631B2 (ja) * | 1995-12-21 | 2003-12-10 | 株式会社アムニオテック | ヒト由来の天然コラーゲン膜からなる医用材料 |
US5939323A (en) * | 1996-05-28 | 1999-08-17 | Brown University | Hyaluronan based biodegradable scaffolds for tissue repair |
JP3563216B2 (ja) * | 1996-10-14 | 2004-09-08 | 株式会社アムニオテック | 医用代替膜及びその製造方法 |
US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US6152142A (en) * | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
US5932205A (en) * | 1997-07-24 | 1999-08-03 | Wang; Ming X. | Biochemical contact lens for treating photoablated corneal tissue |
US6143315A (en) * | 1997-07-24 | 2000-11-07 | Wang; Ming X. | Biochemical contact lens for treating injured corneal tissue |
US6371992B1 (en) * | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
US6432710B1 (en) * | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
US6734018B2 (en) * | 1999-06-07 | 2004-05-11 | Lifenet | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US6312474B1 (en) * | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
US6432712B1 (en) * | 1999-11-22 | 2002-08-13 | Bioscience Consultants, Llc | Transplantable recellularized and reendothelialized vascular tissue graft |
US6479064B1 (en) * | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
US6428802B1 (en) * | 1999-12-29 | 2002-08-06 | Children's Medical Center Corp. | Preparing artificial organs by forming polylayers of different cell populations on a substrate |
US6866686B2 (en) * | 2000-01-28 | 2005-03-15 | Cryolife, Inc. | Tissue graft |
EP1315796B1 (en) * | 2000-08-16 | 2006-07-12 | Duke University | Decellularized tissue engineered constructs and tissues |
MXPA03002414A (es) * | 2000-09-18 | 2004-07-08 | Organogenesis Inc | Protesis con injerto de hoja plana tratada por bioingenieria y su uso. |
JP4451658B2 (ja) * | 2001-10-18 | 2010-04-14 | ライフセル コーポレーション | 組織および器官のリモデリング |
US7497602B2 (en) | 2007-02-08 | 2009-03-03 | Wen-Cheng Lien | Three dimension collapsible lampshade |
-
2002
- 2002-03-26 US US10/106,653 patent/US20030187515A1/en active Pending
-
2003
- 2003-03-26 ES ES03745621.7T patent/ES2526088T3/es not_active Expired - Lifetime
- 2003-03-26 ES ES13181876T patent/ES2710024T3/es not_active Expired - Lifetime
- 2003-03-26 CA CA2479903A patent/CA2479903C/en not_active Expired - Lifetime
- 2003-03-26 MX MXPA04009188A patent/MXPA04009188A/es active IP Right Grant
- 2003-03-26 US US10/397,867 patent/US20040048796A1/en not_active Abandoned
- 2003-03-26 CN CNA038120968A patent/CN1791331A/zh active Pending
- 2003-03-26 AU AU2003226018A patent/AU2003226018B2/en not_active Expired
- 2003-03-26 JP JP2003579744A patent/JP4615223B2/ja not_active Expired - Lifetime
- 2003-03-26 EP EP13182157.1A patent/EP2700309B1/en not_active Expired - Lifetime
- 2003-03-26 NZ NZ535799A patent/NZ535799A/en not_active IP Right Cessation
- 2003-03-26 WO PCT/US2003/009304 patent/WO2003082201A2/en active Search and Examination
- 2003-03-26 EP EP20030745621 patent/EP1575572B1/en not_active Expired - Lifetime
- 2003-03-26 EP EP13181876.7A patent/EP2702871B1/en not_active Expired - Lifetime
- 2003-03-26 EP EP18178249.1A patent/EP3412322A1/en not_active Withdrawn
- 2003-03-26 KR KR1020047015383A patent/KR100999247B1/ko active IP Right Grant
- 2003-03-26 DK DK13182157.1T patent/DK2700309T3/da active
- 2003-03-26 DK DK13181876.7T patent/DK2702871T3/en active
- 2003-03-26 IL IL16422003A patent/IL164220A0/xx unknown
- 2003-03-26 PT PT13181876T patent/PT2702871T/pt unknown
-
2004
- 2004-09-22 ZA ZA2004/07650A patent/ZA200407650B/en unknown
- 2004-09-22 IL IL164220A patent/IL164220A/en active IP Right Grant
-
2006
- 2006-03-21 HK HK06103595.7A patent/HK1085384A1/xx not_active IP Right Cessation
-
2008
- 2008-06-12 AU AU2008202604A patent/AU2008202604B2/en not_active Expired
-
2010
- 2010-07-09 JP JP2010156978A patent/JP5931327B2/ja not_active Expired - Lifetime
-
2011
- 2011-04-06 AU AU2011201662A patent/AU2011201662B2/en not_active Expired
-
2014
- 2014-01-31 JP JP2014016360A patent/JP5993387B2/ja not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140023282A (ko) * | 2011-02-14 | 2014-02-26 | 미메딕스 그룹 인크. | 가교제로 변형된 조직 이식편 및 그것의 제조 및 사용 방법 |
KR102118457B1 (ko) * | 2011-02-14 | 2020-06-03 | 미메딕스 그룹 인크. | 가교제로 변형된 조직 이식편 및 그것의 제조 및 사용 방법 |
US10869952B2 (en) | 2011-02-14 | 2020-12-22 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US10869951B2 (en) | 2011-02-14 | 2020-12-22 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
KR20150138157A (ko) * | 2013-01-09 | 2015-12-09 | 아이에스이 프로페셔널 테스팅 앤드 컨설팅 서비시즈, 인코퍼레이티드 | 비-포유류 조직으로부터의 세포제거된 생체재료 |
KR102284982B1 (ko) | 2013-01-09 | 2021-08-03 | 넥스트젠 바이오로직스, 아이엔씨. | 비-포유류 조직으로부터의 세포제거된 생체재료 |
US11660376B2 (en) | 2013-01-09 | 2023-05-30 | NeXtGen Biologies, Inc. | Decellularized biomaterial from non-mammalian tissue |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100999247B1 (ko) | 콜라겐 생구조물 및 그 제조방법 및 용도 | |
US11752174B2 (en) | Placental tissue grafts and improved methods of preparing and using the same | |
JP5109030B2 (ja) | シート状組成物 | |
Elahi et al. | Amniotic membrane as a scaffold for periodontal tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131122 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151123 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171124 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181122 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |